300 related articles for article (PubMed ID: 26939702)
41. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
[TBL] [Abstract][Full Text] [Related]
42. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.
Zhang Q; Zhao W; Ye C; Zhuang J; Chang C; Li Y; Huang X; Shen L; Li Y; Cui Y; Song J; Shen B; Eliaz I; Huang R; Ying H; Guo H; Yan J
Oncotarget; 2015 Nov; 6(35):37335-48. PubMed ID: 26484567
[TBL] [Abstract][Full Text] [Related]
43. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
[TBL] [Abstract][Full Text] [Related]
44. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
[TBL] [Abstract][Full Text] [Related]
45. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
46. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
47. An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
Perotti V; Baldassari P; Molla A; Nicolini G; Bersani I; Grazia G; Benigni F; Maurichi A; Santinami M; Anichini A; Mortarini R
Oncogene; 2019 May; 38(22):4384-4396. PubMed ID: 30710146
[TBL] [Abstract][Full Text] [Related]
48. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of CircRNA BCRC4 regulates cell apoptosis and MicroRNA-101/EZH2 signaling in bladder cancer.
Li B; Xie F; Zheng FX; Jiang GS; Zeng FQ; Xiao XY
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):886-890. PubMed ID: 29270748
[TBL] [Abstract][Full Text] [Related]
50. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy.
Chen X; Wang C; Lu D; Luo H; Li S; Yin F; Luo Z; Cui N; Kong L; Wang X
Bioorg Med Chem; 2023 Aug; 91():117386. PubMed ID: 37379621
[TBL] [Abstract][Full Text] [Related]
52. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer.
Nerlakanti N; Yao J; Nguyen DT; Patel AK; Eroshkin AM; Lawrence HR; Ayaz M; Kuenzi BM; Agarwal N; Chen Y; Gunawan S; Karim RM; Berndt N; Puskas J; Magliocco AM; Coppola D; Dhillon J; Zhang J; Shymalagovindarajan S; Rix U; Kim Y; Perera R; Lawrence NJ; Schonbrunn E; Mahajan K
Mol Cancer Ther; 2018 Dec; 17(12):2796-2810. PubMed ID: 30242092
[TBL] [Abstract][Full Text] [Related]
53. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer.
Coleman DJ; Gao L; Schwartzman J; Korkola JE; Sampson D; Derrick DS; Urrutia J; Balter A; Burchard J; King CJ; Chiotti KE; Heiser LM; Alumkal JJ
Sci Rep; 2019 Mar; 9(1):3823. PubMed ID: 30846826
[TBL] [Abstract][Full Text] [Related]
54. ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
He L; Chen C; Gao G; Xu K; Ma Z
Aging (Albany NY); 2020 Mar; 12(5):4547-4557. PubMed ID: 32163373
[TBL] [Abstract][Full Text] [Related]
55. Bromodomain-Containing Protein 4 (BRD4) Inhibition Sensitizes Palomid 529-Induced Anti-Renal Cell Carcinoma Cell Activity in Vitro and in Vivo.
Xing ZY; Wang Y; Cheng L; Chen J; He XZ; Xing W
Cell Physiol Biochem; 2018; 50(2):640-653. PubMed ID: 30308518
[TBL] [Abstract][Full Text] [Related]
56. miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling.
Guo Y; Ying L; Tian Y; Yang P; Zhu Y; Wang Z; Qiu F; Lin J
FEBS J; 2013 Sep; 280(18):4531-8. PubMed ID: 23815091
[TBL] [Abstract][Full Text] [Related]
57. Role of BRD4 in hematopoietic differentiation of embryonic stem cells.
Rodriguez RM; Suarez-Alvarez B; Salvanés R; Huidobro C; Toraño EG; Garcia-Perez JL; Lopez-Larrea C; Fernandez AF; Bueno C; Menendez P; Fraga MF
Epigenetics; 2014 Apr; 9(4):566-78. PubMed ID: 24445267
[TBL] [Abstract][Full Text] [Related]
58. Forkhead Box R2 Knockdown Decreases Chemoresistance to Cisplatin via MYC Pathway in Bladder Cancer.
Li Y; Zu X; Hu X; Wang L; He W
Med Sci Monit; 2019 Nov; 25():8928-8939. PubMed ID: 31761897
[TBL] [Abstract][Full Text] [Related]
59. Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA.
Kumari K; Das B; Adhya A; Chaudhary S; Senapati S; Mishra SK
Cell Death Dis; 2018 Feb; 9(2):152. PubMed ID: 29396474
[TBL] [Abstract][Full Text] [Related]
60. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
